The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Assistant settings

journal:Molecular Cancer Therapeutics

Authors:David M. Briere; Shuai Li; Andrew Calinisan; Niranjan Sudhakar; Ruth Aranda; Lauren Hargis; David H. Peng; Jiehui Deng; Lars D. Engstrom; Jill Hallin; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Kwok-Kin Wong; James G. Christensen; Peter Olson

Publication date:2021-6-

DOI：10.1158/1535-7163.mct-20-0462

Article link:http://dx.doi.org/10.1158/1535-7163.mct-20-0462

Article Source:American Association for Cancer Research (AACR)。


Remark:

This post has been completed

Completed attachments will be deleted within 24 hours.